NPY and glucose measurement: And rosiglitazone can regulate the phosphatidylinositol 3-kinase/Akt signaling pathway and inhibit NPY gene expression in the hypothalamus though promoting the activation of RB1, which significantly reducing fasting blood glucose and improving glucose tolerance, have positive significance for the clinical treatment of diabetes [43].